All Stories

  1. Integrating hypertriglyceridemia, inflammation, and β-cell stress in clozapine- and olanzapine-associated pancreatitis
  2. A two-speed β-cell failure model for diabetes in non-obese Asian patients with schizophrenia
  3. Beyond fatality signals: Reconsidering clozapine safety through severe gastrointestinal hypomotility and real-world clinical complexity
  4. The “GABAergic Brake” on the Spinal Defecation Reflex: A Proposed Neurobiological Model Explaining Clozapine‐ and Benzodiazepine‐Induced Gastrointestinal Hypomotility and Ogilvie's Syndrome
  5. Optimizing Clozapine Monitoring in Older Adults: A Proposal for Ethnicity‐ and Sex‐Informed Monitoring in Japanese Geriatric Patients
  6. Brain-heart axis in burning mouth syndrome: a neurobiological perspective
  7. Sensory Blurring in Nociplastic Pain: The Role of Descending Inhibitory Dysfunction and Gut–Brain Axis Alterations in Older Adults
  8. Optimizing Management of Treatment‐Resistant Schizophrenia in Japan: Promoting a Refined Clozapine Titration Protocol and Addressing the ‘Clozapine Ceiling’ through Glutamatergic Modulation
  9. Differentiating Trigeminal Neuralgia From Persistent Idiopathic Dentoalveolar Pain and Persistent Idiopathic Facial Pain in Oral and Maxillofacial Surgery
  10. Loneliness as a Relational Barometer: A Dyadic Perspective on Caregiver Burden
  11. Pharmacological Incongruity of Lacosamide in the Management of Delirium Complicated by Ileus
  12. Brain-Heart Axis in Burning Mouth Syndrome: A Neurobiological Framework
  13. The Contralateral Muscle Reserve: Rethinking Post‐Operative Risk Stratification and Discharge Trajectories in Acute Hip Fracture Care
  14. The Gut–Muscle Axis in Sarcopenia: From Parallel Aging to a Self‐Perpetuating Vicious Cycle
  15. Methodological Limitations and the Necessity of Objective Biomarkers in Linking Oral Frailty to Subjective Sleep Quality
  16. The objective imperative: advancing chronic orofacial pain research with the brain-heart axis
  17. Serum Prolactin Levels as an Intraindividual Biomarker for Guiding Osmotic-Release Oral System-Methylphenidate Therapy: Three Case Reports
  18. Beyond Policy Interventions: Addressing the Persistence of Hypnotic Use and Polypharmacy in Japan's Aging Population
  19. Bridging Metabolomics and Nociception: The Arachidonic Acid–NMDA Receptor Axis in Burning Mouth Syndrome
  20. Beyond Prescriptions: Addressing Stagnation in Benzodiazepine Reduction in Acute Care Geriatric Wards in Japan
  21. Tongue Pressure: A Critical Bridge Between Oral Frailty and Systemic Longevity in Older Adults
  22. Integrating a Biopsychosocial and Neuroscientific Perspective Into Satoyama‐Based Frailty Research
  23. Noise Pareidolia Test for Delirium Prediction: Considering the Role of Dopaminergic Basal Ganglia Circuitry
  24. Attention to Elderspeak: A Call for Dignity-Affirming Communication in Advanced Nursing Care
  25. Effective Treatment With Olanzapine for Burning Mouth Syndrome With Denture Intolerance in an Older Patient: A Case Report
  26. Neuroscience‐Based Nomenclature: Bridging the Knowledge Gap for Safer Medication Management in Older Adult Care
  27. The evolving serotonin syndrome spectrum: from acute syndrome to smoldering presentations and personalized risk management
  28. Age, Sex, and Neuroinflammation: A Unified Mechanism for Burning Mouth Syndrome Driven by Small Fiber Neuropathy and Central Sensitization
  29. A Pharmacological and Critical Review of Caffeine and Alpha‐Lipoic Acid for Burning Mouth Syndrome
  30. Improving Communication With Older Adults Using a Self‐Reflection Questionnaire for Elderspeak: A Preliminary Proposal
  31. Managing Constipation in Older Adults on Atypical Antipsychotics: A Defecation Reflex and Gut Microbiota Approach
  32. The Oral–Brain Axis: A Novel Perspective on Bruxism and Orofacial Pain
  33. Bridging the Mind–Mouth Divide: Neuroscience's Essential Role in Dental Psychosomatic Education
  34. N-methyl-D-aspartate receptor as a therapeutic target for burning mouth syndrome
  35. Beyond Tooth Count: The Interplay of Oral Health, Frailty and Falls
  36. Burning Mouth Syndrome: A Neurological Reappraisal Through Idiopathic Intracranial Hypertension and Glymphatic Dysfunction
  37. Rethinking Burning Mouth Syndrome: A Nociplastic Pain Disorder Shaped by Sexual Dimorphism
  38. Real-World Prescribing Patterns and Treatment Continuation of Amitriptyline Monotherapy and Aripiprazole Augmentation for Medically Unexplained Oral Symptoms/Syndromes in Japan
  39. Commentary on “Examining the combined effects of social isolation and oral dysfunction on cognitive decline in community‐dwelling older Japanese adults”: Proposing a vicious cycle and holistic interventions
  40. Role of Brain Networks in Burning Mouth Syndrome: A Narrative Review
  41. Potential Target Receptors for the Pharmacotherapy of Burning Mouth Syndrome
  42. Memantine-Associated Decrease in Renal Function and Hyperuricemia
  43. Estrogen-Mediated Neural Mechanisms of Sex Differences in Burning Mouth Syndrome
  44. Life-threatening Neuroleptic Malignant Syndrome and Its Mechanism
  45. Pathogenesis of Orofacial Pain Based on Brain Circuits
  46. Molecular Mechanisms of Pain Regulation by Sex Hormones in Individuals With Burning Mouth Syndrome
  47. Challenges of Constipation in People Suffering from Schizophrenia: A Narrative Review
  48. Perioperative administration of esketamine during cesarean section is a double-edged sword
  49. Application of virtual reality technology improves the functionality of brain networks in individuals experiencing pain
  50. Investigating the Influence of Birth Month on the Incidence of Burning Mouth Syndrome
  51. Merits and demerits of administering esketamine in preventing postpartum depression following cesarean section
  52. Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people
  53. Facial aesthetics is shaped not only by genetic predispositions but also by the cultural norms and values
  54. The Role of the Gut Microbiota in Individuals with Irritable Bowel Syndrome: A Scoping Review
  55. Mechanisms of Drug-Associated Burning Mouth Syndrome
  56. Suicidality in individuals experiencing chronic orofacial pain
  57. The role of oral microbiota in the pathogenesis of burning mouth syndrome
  58. Chronic orofacial pain
  59. Responsiveness to amitriptyline in burning mouth syndrome
  60. Amitriptyline at low dose for burning mouth syndrome
  61. The effective perospirone augmentation with clonazepam for treatment‐resistant burning mouth syndrome: A case report
  62. Goal Attainment Scaling in Patients With Burning Mouth Syndrome: A Real-World Clinical Study Protocol
  63. QTc Shortening on Electrocardiogram With Amitriptyline May Indicate No Effect on Pain Relief in Burning Mouth Syndrome
  64. Guanfacine Used With Antipsychotics May Cause Bradycardia to Become Apparent After Discontinuation of Antipsychotics
  65. Spontaneous Pneumomediastinum in a Middle-Aged Female Patient With Schizophrenia: A Case Report
  66. Leukopenia associated with lamotrigine initiation after COVID-19 vaccine booster: A case report and literature review
  67. Effect of magnesium oxide with probiotics on bowel movements in elderly orthopedic patients with chronic constipation: a retrospective chart review
  68. Clinical Features and Variations of Pain Expressions in 834 Burning Mouth Syndrome Patients With or Without Psychiatric Comorbidities
  69. Burning mouth syndrome needs to consider the gut-brain axis from three types of pain: nociceptive, neuropathic, and nociplastic pain
  70. Poststroke Mania During the COVID-19 Pandemic
  71. Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion
  72. Beware of attention‐deficit/hyperactivity disorder (ADHD) in older adults
  73. Dental conditions in patients with medically unexplained oral symptoms
  74. Sepsis associated with sodium glucose co‐transporter 2 inhibitor in an elderly patient with chronic kidney disease
  75. Comment on: The assessment of the long-term prognosis of burning mouth syndrome following treatment necessitates a reappraisal
  76. Letter to the Editor: Venous Neurovascular Compression and Chronic Orofacial Pain
  77. Antiviral Therapy for COVID-19 May Not Reduce Stroke Complications
  78. Preventing dehydration can help ensure safe use of psychotropic medications in the elderly
  79. Somatization and Medicalization in Patients with Unexplained Orofacial Pain
  80. Case series of drug-induced open bite: Extrapyramidal symptoms related to psychotropic medications
  81. Serotonin Paradox in Burning Mouth Syndrome
  82. Mild Decrease in Blood Glucose Levels May Predict Efficacy of Antipsychotic Lurasidone
  83. Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study
  84. Omicron variant infections and multiple strokes in older adults
  85. Beware of bihemispheric stroke after Omicron variant infection in the elderly
  86. Clozapine-Induced Fever and Plasma Cytokine Changes in a Patient With Schizophrenia
  87. Two-hit theory by estrogen in burning mouth syndrome
  88. Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
  89. Duloxetine-induced Hyponatremia Can Occur in Not Only Syndrome of Inappropriate Secretion of Antidiuretic Hormone but Also Cerebral Salt Wasting Syndrome
  90. Factors associated with the frequency of respiratory rate measurement by hospital nurses: a multicentre cross-sectional study
  91. How to facilitate respiratory rate measurement in the emergency room
  92. Beware of serotonin syndrome during the COVID-19 pandemic
  93. Beware of serotonin overload in pharmacotherapy for elderly patients with burning mouth syndrome
  94. The Effectiveness and Adverse Events of Amitriptyline and Aripiprazole in Very Elderly Patients With BMS
  95. Neuroleptic malignant syndrome associated with COVID-19 vaccination
  96. BRASH syndrome associated with angiotensin receptor blocker and SGLT2 inhibitor
  97. Metabolic Effects of Clozapine Administration Based on Sex Differences and the Relationships Between Dosage and Prolactin Levels: An Observational Study
  98. Foreign accent syndrome associated with left insula infarction after COVID-19 pneumonia
  99. Beware of Biphasic Anaphylaxis
  100. Biliary pseudolithiasis in an older patient treated with lascufloxacin
  101. Beware of traumatic anosmia in COVID-19 pandemic
  102. Long‐term preoperative use of zolpidem is associated with postoperative delirium in elderly patients undergoing hip surgery
  103. Prevalence and predictors of laxatives use in clozapine-related constipation: an observational study
  104. Careful use of clonazepam and alpha lipoid acid in burning mouth syndrome treatment
  105. Atypical diabetes mellitus caused by olanzapine
  106. Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes
  107. Severe hypoglycemia in an elderly patient with Alzheimer's disease and with sepsis: The role of neurotransmitters on glucose regulation
  108. Cognitive decline due to the cerebral cavernous malformations
  109. Reply to the comments on “Aging is independently associated with an increasing normal respiratory rate among older adults without pulmonary disease and chronic heart failure”
  110. Eosinophilic pneumonia during treatment with clozapine: reports from a retrospective case series
  111. Contrasting characters of quick methods to measure respiratory rate in a clinical setting
  112. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, may be a double-edged sword for patients with advanced Parkinson's disease
  113. The effect of probiotics on bowel movement and metabolic parameters in schizophrenia patients: a retrospective chart review
  114. Correspondence- ‘Role of Diffusion Weighted Imaging in Differentiating Benign from Pathological Vertebral Collapse using ADC Values’; Is It Possible to Discriminate Multiple Myeloma with Magnetic Resonance Imaging?
  115. Correspondence: Association of Serum Uric Acid Level with the Severity of Brain Injury and Patient’s Outcome in Severe Traumatic Brain Injury
  116. Letter Regarding the Article, ‘Hyponatremia in Patients Admitted with Stroke’; From the Viewpoint of Similarity to Hyponatremia Associated with Traumatic Brain Injury
  117. Therapeutic Dose of Amitriptyline for Older Patients with Burning Mouth Syndrome
  118. Acute psychosis secondary to atypical Bickerstaff brainstem encephalitis
  119. Aging is independently associated with an increasing normal respiratory rate among an older adult population in a clinical setting: A cross‐sectional study
  120. Primary prevention of Clostridioides difficile infection with combination probiotics
  121. Recurrence of eosinophilic pneumonia after clozapine treatment
  122. Duloxetine and Angiotensin II Receptor Blocker Combination Potentially Induce Severe Hyponatremia in an Elderly Woman
  123. A Comparison of Methods to Count Breathing Frequency
  124. Letter to the Editor on ‘PCR as a Diagnostic Tool for Extra-Pulmonary Tuberculosis’
  125. Is primary prevention of Clostridioides difficile infection possible with combination probiotics in elderly orthopedic patients?
  126. Correspondence: ‘Influenza as a Cause of SIADH Related Hyponatremia’
  127. Combination probiotics may prevent Clostridium difficile infection among elderly patients undergoing an orthopedic surgery
  128. Correspondence: Curious Case of Myocardial Infarction Caused by Lung Abscess- From the Viewpoint of Type 2 Myocardial Infarction by Chest Trauma
  129. Burning mouth syndrome: The challenge of an aging population
  130. Serum electrolyte levels may be associated with prefrontal hemodynamic responses in near infrared spectroscopy
  131. An increase in salivary flow with amitriptyline may indicate treatment resistance in burning mouth syndrome
  132. Serum prolactin levels are associated with prefrontal hemodynamic responses using near-infrared spectroscopy in male psychotic patients treated with antipsychotics
  133. Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient
  134. 4G-β-D-galactosylsucrose as a prebiotics may improve underweight in inpatients with schizophrenia
  135. The QTc shortening with amitriptyline may indicate treatment resistance in chronic nonorganic orofacial pain
  136. Adrenaline reversal may be an unwarranted distraction during emergency cardiovascular care for patients treated with antipsychotics
  137. Responsibility of the doctor who prescribes serotonin and noradrenaline reuptake inhibitors for patients with chronic musculoskeletal pain
  138. Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia
  139. Carnitine may prevent health problems in hyperprolactinemia
  140. antipsychotic-induced hypoglycemia
  141. Iron Depletion Affects Dopamine Neurotransmissions
  142. Cerebral edema secondary to psychogenic polydipsia induced by tandospirone as add-on to olanzapine therapy
  143. Does olanzapine impair pancreatic beta-cell function directly?
  144. Olanzapine-induced severe hyperglycemia was completely reversed by the restoration of insulin secretion after switching to aripiprazole and initiating insulin therapy
  145. Erratum: Riwa Ozasa, Tetsuya Okada, Satomi Nadanaka, Takahiko Nagamine, Alisha Zyryanova, Heather Harding, David Ron, Kazutoshi Mori (2013) The Antipsychotic Olanzapine Induces Apoptosis in Insulin-secreting Pancreatic ^|^beta; Cells by Blocking PERK-m...
  146. The Antipsychotic Olanzapine Induces Apoptosis in Insulin-secreting Pancreatic β Cells by Blocking PERK-mediated Translational Attenuation
  147. Lithium Intoxication Associated with Angiotensin II Type 1 Receptor Blockers in Women
  148. Metabolic Effects of Sodium Valproate on Atypical Antipsychotics in Japanese Psychotic Patients
  149. Antipsychotic-induced hyperthermia in patients with behavioral and psychological symptoms of dementia
  150. Are psychotropic drugs involved in gallstone-induced acute abdomen in inpatients with schizophrenia?
  151. Carnitine Deficiency and Severe Hypoglycemia Associated with Valproic Acid
  152. Duloxetine-induced Hyponatremia in the Elderly
  153. Hypoprolactinemia and Extrapyramidal Symptoms in Male Schizophrenia or Psychotic Affective Disorder Patients Treated with Aripiprazole
  154. Metabolic Effects of Valproic Acid Augmentation in Male Schizophrenic Patients
  155. Are combination therapies with aripiprazole and other antipsychotics pharmacologically rational?
  156. What does antipsychotic-associated hypoprolactinemia mean in patients with chronic schizophrenia?
  157. Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
  158. Severe Hyperglycemia Induced by Olanzapine was Improved with a Recovery of Insulin Secretion after Switching to Risperidone and Introducing Insulin Therapy
  159. Olanzapine-induced Elevation of Serum Triglyceride Levels in a Normal Weight Patient with Schizophrenia
  160. Direct metabolic effects of risperidone and olanzapine in Japanese schizophrenic patients
  161. Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics
  162. Attitudes toward death in rural areas of Japan